CVCVHealthcare · Medical Devices

CV Stock Forecast: CapsoVision, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.11
−3.17% on the day

The median 12-month analyst price target for CapsoVision, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$327.6M
Ticker Nerd rank
18/ 100
Median analyst target
$9.50
Analysts covering
2
Revenue$3.6M+9.9% y/y
Operating income−$7.6M
Net income−$7.5M
Free cash flow−$8.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.3%
1M
−8.5%
YTD
−42.8%
1Y
+14.6%
From 52W high
−57.6%
From 52W low
+31.7%
$5
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores CapsoVision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
63
Momentum
60
Value
41
Revisions
39
Issuance
36
Accruals
23
Quality
13
Growth
10

Volatility (63): The share price has been relatively steady.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26CVHigh $10.00Median $9.50Low $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$9.00
Low
$9.50
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Mar 2026BenchmarkMaintainsSpeculative Buy$14 → $10
31 Dec 2025BenchmarkMaintainsSpeculative Buy—
28 July 2025BenchmarkInitiatesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CV.

Market Radar

This page is one stock. Monday covers all of them.

CV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, CapsoVision, Inc. returned +14.6% against +6.9% for the S&P 500, dividends included.

CV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26CVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
23.5×

Cheaper than 7% of US stocks

Price / book
12.4×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
51.4%

Higher than 63% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−125.0%

Higher than 11% of US stocks

Return on assets
−62.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CapsoVision, Inc. has a market value of $327.6M and an enterprise value of $306.6M.

  • Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter grew 9.9% year on year.

  • Net income over the same four quarters: −$29.8M, a −214.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$27.9M.

  • Shares outstanding: 50.0M.

  • CapsoVision, Inc. employs 99 people — $140K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CVCapsoVision, Inc.$327.6M18
VMDViemed Healthcare, Inc.$323.9M99
MASS908 Devices, Inc.$355.7M77
INFUInfuSystem Holdings, Inc.$285.8M100
CERSCerus Corp.$373.6M96
TMCITreace Medical Concepts, Inc.$274.6M55
MOBIMobia Medical, Inc.$392.1M2

Take a look at CV’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own CapsoVision, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CV

What is the CV stock price forecast for 2026-2027?

The median 12-month analyst price target for CapsoVision, Inc. is $9.5, with estimates ranging from $9 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CV stock a buy right now?

Of the 2 analysts covering CapsoVision, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CapsoVision, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CV?

As at 21 Nov 2026, CapsoVision, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (63 of 100).

Will CV stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $9.5, and Ticker Nerd's factor model ranks CapsoVision, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CV stock forecast for 2030?

No analyst covering CapsoVision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $10 over the next 12 months.

How has CV stock performed over the past year?

CapsoVision, Inc. returned +14.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CapsoVision, Inc. do?

CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging. The company’s products are designed to help clinicians visualize the GI tract for diagnostic and screening purposes, with a focus on detecting abnormalities such as bleeding, inflammation, and polyps.

Company

About CapsoVision, Inc.

CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging. The company’s products are designed to help clinicians visualize the GI tract for diagnostic and screening purposes, with a focus on detecting abnormalities such as bleeding, inflammation, and polyps. Its portfolio includes the CapsoCam Plus capsule endoscopy system for small-bowel visualization, along with cloud-based and direct-view software tools that support image retrieval and review. CapsoVision also offers solutions for colon imaging and related GI applications, combining advanced imaging with AI-enabled workflows to improve clinical efficiency. Based in Saratoga, California, CapsoVision serves hospitals, gastroenterology practices, and other medical providers seeking non-invasive tools for internal GI diagnostics.

CEO Mr. Kang-Huai Wang · 99 employees · United States · https://capsovision.com